Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002400
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients
Sponsor:
Pharmacia and Upjohn
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
An Open-Label Randomized Study of Delavirdine Mesylate Rescriptor in Combination With Zidovudine Retrovir and Two Doses of Indinavir Crixivan Versus Zidovudine Lamivudine Epivir and Indinavir in HIV-1-Infected Individuals
Status:
COMPLETED
Status Verified Date:
1999-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine DLV plus zidovudine ZDV plus 2 doses of indinavir IDV or ZDV plus IDV plus lamivudine 3TC This study also examines how the body processes DLV when it is given in combination with other drugs
Detailed Description:
In this multicenter open-label study 45 HIV-1-positive patients receive either combination drug therapy with delavirdine DLV zidovudine ZDV and indinavir IDV or combination drug therapy with ZDV lamivudine 3TC and IDV NOTE Patients are treated for 24 weeks and may opt to continue on study for 24 additional weeks if HIV-1 RNA is less than 5000 copiesml or at the investigators discretion
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 0063 | None | None | None |